Tumor Ablation Market Outlook, Key Vendors, Segment, Growth Opportunities by 2016 to 2030
Market Analysis
The global Tumor Ablation Market is expected to cross USD
2,459.74 million by 2030 at a CAGR of 11.81% during the forecast period
2022-2030. Tumor ablation is a technique that is minimally invasive and
commonly used for treating tumors in the lung, bone, kidney and liver. During
this process, thermal energy is utilized to cool or heat tissues to cytotoxic
levels. Under its classification, there are various modalities used worldwide:
irreversible electroporation, cryoablation, high-intensity focused ultrasound,
laser, microwave and radiofrequency. Every technique though similar in purpose
possess optimal and specific indications. Tumor ablation is a vital choice for
those who have failed radiotherapy or chemotherapy or is not a candidate for
surgery. It is also considered as the potential first-line treatment especially
in patients with benign tumors in the liver or small hepatocellular carcinomas.
This is a convenient and excellent treatment choice over the other conventional
surgical methods.
Key Players
Leading Tumor Ablation Market Players Profile include
Covidien PL, Misonix Inc., Galil Medical, Inc, Biotronik,
Boston Scientific Corporation, Neuwave Medical, Inc., Healthtronics Inc., AngioDynamics
Inc., EDAP TMS, Medtronic Plc., and SonaCare Medical.
Market Segmentation
Market Research Future report offers a comprehensive
segmental analysis of the Tumor
Ablation Market Insights on the basis of technology, treatment,
application and end-user.
·
Based on technology, it is segmented into
cryoablation, irreversible electroporation, microwave, radiofrequency and
others. Of these, radiofrequency will dominate the tumor ablation market during
the forecast period. Prominent use of this technology to remove solid tumor and
its specificity has resulted to its growth. Also, this method’s efficiency is
expected to spur the segment growth. This will be followed by microwave
ablation technology that is projected to have a remunerative growth due to the
advantages provided by this technology namely optimal heating of cystic mass,
reduced procedural pain, lesser time, constancy in high temperature and bigger
tumor ablation volume.
·
Based on treatment, the tumor ablation
market is segmented into laparoscopic, percutaneous and surgical. Of these,
surgical will dominate the market during the forecast period owing to rising
prevalence of breast and liver cancer that needs open surgical techniques. This
will be followed by the percutaneous ablation that is projected to grow at the
fastest pace.
·
Based on application, it is segmented
into prostate cancer, bone cancer, breast
cancer, lung cancer, liver cancer and others. Of these, liver cancer will
have the largest share in the market owing to rising cases of both bile duct as
well as primary liver cancers. Of these, lung cancer will lead the market
during the forecast period owing to rising cases of the disease.
·
Based on end-user, the tumor ablation
market is segmented into research institute, surgical and ablation centers and
hospitals. Of these, hospitals will dominate the market due to increasing
practices to visit the hospital for well-being along with the availability of
various facilities in hospitals.
Regional Analysis
By region, the Tumor Ablation Market Outlook covers
growth opportunities and latest trends across Americas, Europe, Asia Pacific
and Middle East and Africa. Of these, Americas will remain head and shoulders
over other regions in the market. The growth can be attributed to factors such
as increasing incidences of cancer amid rising elderly population, use of
advanced healthcare facilities, favorable reimbursement policies, and
increasing awareness regarding cancer detection as well as treatment. The tumor
ablation market in Europe will grab the second position owing to rising
prevalence of cancer coupled with increasing healthcare expenditure. The tumor
ablation market in the APAC region will grow at the fastest pace due to high
demand for advanced healthcare technologies, constantly growing investment in
healthcare and rising geriatric population. On the other hand, the tumor
ablation market in the Middle East and Africa will have a minimal share owing
to poor medical facilities, dearth of technical knowledge and underdeveloped
healthcare sector.
March 2019- CLS (Clinical Laserthermia Systems AB) stated
that both clinical studies as well as outcomes of the imILT cancer
immunotherapy that is heat induced for tumors will be highlighted at ECIO
(European Conference on Interventional Oncology) at Netherlands on April 8-11,
2019. CLS will also take part on a hands-on, educational workshop for “tumor
ablation” highlighting its TRANSBERG thermal therapy system for high-precision,
image-guided laser ablation.
Market Research
Future (MRFR) enable customers to unravel the complexity of various industries
through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
Contact us:
Market Research
Future (part of Wantstats Research and Media Private Limited),
99 Hudson
Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment